ES2915382T3 - Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer - Google Patents
Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2915382T3 ES2915382T3 ES15842576T ES15842576T ES2915382T3 ES 2915382 T3 ES2915382 T3 ES 2915382T3 ES 15842576 T ES15842576 T ES 15842576T ES 15842576 T ES15842576 T ES 15842576T ES 2915382 T3 ES2915382 T3 ES 2915382T3
- Authority
- ES
- Spain
- Prior art keywords
- peg
- adi
- cancer
- arginine deiminase
- radi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03006—Arginine deiminase (3.5.3.6)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051182P | 2014-09-16 | 2014-09-16 | |
| PCT/US2015/050354 WO2016044376A1 (en) | 2014-09-16 | 2015-09-16 | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2915382T3 true ES2915382T3 (es) | 2022-06-22 |
Family
ID=55453727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15842576T Active ES2915382T3 (es) | 2014-09-16 | 2015-09-16 | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9789170B2 (OSRAM) |
| EP (2) | EP3193913B1 (OSRAM) |
| JP (2) | JP6782230B2 (OSRAM) |
| KR (1) | KR102730989B1 (OSRAM) |
| CN (2) | CN114522225B (OSRAM) |
| AU (1) | AU2015317848B2 (OSRAM) |
| CA (1) | CA2961602A1 (OSRAM) |
| ES (1) | ES2915382T3 (OSRAM) |
| SG (2) | SG11201702103XA (OSRAM) |
| TW (2) | TWI775160B (OSRAM) |
| WO (1) | WO2016044376A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6382934B2 (ja) | 2013-03-15 | 2018-08-29 | ポラリス グループ | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ |
| CN106794229B (zh) | 2014-03-18 | 2020-12-18 | 瑞华药业集团 | 工程化嵌合聚乙二醇化adi和使用方法 |
| KR102730989B1 (ko) | 2014-09-16 | 2024-11-14 | 티디더블유 그룹 | 암 치료용 adi-peg 20 항체에 대한 감소된 교차-반응성을 갖는 아르기닌 데이미나아제 |
| CN119950689A (zh) | 2016-07-05 | 2025-05-09 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| BR112019003032A2 (pt) | 2016-08-18 | 2019-05-14 | Univ Duke | inibidores de invasão intracelular |
| BR112019005935A2 (pt) * | 2016-09-29 | 2019-06-11 | Meharry Medical College | inibidores bacterianos |
| WO2018085551A2 (en) * | 2016-11-02 | 2018-05-11 | Polaris Group | Formulations of pegylated arginine deiminase |
| EP3609527B1 (en) * | 2017-03-29 | 2025-07-30 | Polaris Group | Protein conjugates |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| US6635462B1 (en) | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6180387B1 (en) | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
| IT1298918B1 (it) | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| WO2002009741A1 (en) | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| AU2001289132A1 (en) | 2000-11-28 | 2002-06-11 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| JP4733393B2 (ja) | 2002-11-18 | 2011-07-27 | ポラリス・グループ | インビボでウイルス複製を阻害する方法 |
| CN1536079A (zh) * | 2003-04-09 | 2004-10-13 | 上海复旦张江生物医药股份有限公司 | 修饰的精氨酸脱亚氨酶 |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| WO2005052145A2 (en) | 2003-10-07 | 2005-06-09 | University Of Florida | Recombinant alkaliizing bacteria |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| EP2173732A4 (en) | 2007-07-04 | 2011-09-07 | Reddys Lab Ltd Dr | PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC |
| US20090238813A1 (en) | 2007-12-28 | 2009-09-24 | Board Of Regents, The University Of Texas System | Compositions And Methods For Engineered Human Arginine Deiminases |
| US20120015049A1 (en) | 2009-01-14 | 2012-01-19 | Lin Zhang | Microrna biomarker in cancer |
| CN101591649B (zh) * | 2009-07-10 | 2013-02-13 | 江苏泰康生物医药有限公司 | 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用 |
| WO2011053871A2 (en) | 2009-10-30 | 2011-05-05 | Life Technologies Corporation | Multi-primer assay for mycoplasma detection |
| CN101812438B (zh) * | 2010-03-25 | 2014-08-27 | 江苏泰康生物医药有限公司 | 一种精氨酸脱亚氨酶突变体及其制备与应用 |
| JP2013527223A (ja) | 2010-06-02 | 2013-06-27 | フレゼニウス・カビ・オンコロジー・リミテッド | ラパマイシンエステルの安定な医薬組成物 |
| US20120148559A1 (en) * | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US8663967B2 (en) | 2011-08-22 | 2014-03-04 | Jiangsu T-Mab Biopharma Co., Ltd. | Arginine deiminase mutant and preparation and application thereof |
| EP4582090A3 (en) | 2012-04-04 | 2025-09-17 | Polaris Group | Composition comprising pegylated arginine deiminase |
| JP6382934B2 (ja) | 2013-03-15 | 2018-08-29 | ポラリス グループ | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ |
| CN106794229B (zh) | 2014-03-18 | 2020-12-18 | 瑞华药业集团 | 工程化嵌合聚乙二醇化adi和使用方法 |
| KR102730989B1 (ko) | 2014-09-16 | 2024-11-14 | 티디더블유 그룹 | 암 치료용 adi-peg 20 항체에 대한 감소된 교차-반응성을 갖는 아르기닌 데이미나아제 |
-
2015
- 2015-09-16 KR KR1020177010232A patent/KR102730989B1/ko active Active
- 2015-09-16 TW TW109133681A patent/TWI775160B/zh active
- 2015-09-16 SG SG11201702103XA patent/SG11201702103XA/en unknown
- 2015-09-16 CN CN202210112607.3A patent/CN114522225B/zh active Active
- 2015-09-16 JP JP2017515843A patent/JP6782230B2/ja active Active
- 2015-09-16 ES ES15842576T patent/ES2915382T3/es active Active
- 2015-09-16 AU AU2015317848A patent/AU2015317848B2/en active Active
- 2015-09-16 US US14/855,661 patent/US9789170B2/en active Active
- 2015-09-16 EP EP15842576.9A patent/EP3193913B1/en active Active
- 2015-09-16 TW TW104130733A patent/TWI708612B/zh active
- 2015-09-16 CN CN201580057712.XA patent/CN107073085B/zh active Active
- 2015-09-16 EP EP22172372.9A patent/EP4104853A1/en active Pending
- 2015-09-16 SG SG10202002557SA patent/SG10202002557SA/en unknown
- 2015-09-16 CA CA2961602A patent/CA2961602A1/en active Pending
- 2015-09-16 WO PCT/US2015/050354 patent/WO2016044376A1/en not_active Ceased
-
2020
- 2020-10-19 JP JP2020175282A patent/JP6961061B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG10202002557SA (en) | 2020-04-29 |
| CA2961602A1 (en) | 2016-03-24 |
| CN114522225B (zh) | 2025-07-25 |
| JP6961061B2 (ja) | 2021-11-05 |
| TWI775160B (zh) | 2022-08-21 |
| CN107073085B (zh) | 2022-02-18 |
| EP3193913A4 (en) | 2018-07-18 |
| KR102730989B1 (ko) | 2024-11-14 |
| SG11201702103XA (en) | 2017-04-27 |
| CN114522225A (zh) | 2022-05-24 |
| AU2015317848B2 (en) | 2021-04-22 |
| CN107073085A (zh) | 2017-08-18 |
| EP4104853A1 (en) | 2022-12-21 |
| EP3193913A1 (en) | 2017-07-26 |
| TWI708612B (zh) | 2020-11-01 |
| US20160074487A1 (en) | 2016-03-17 |
| WO2016044376A1 (en) | 2016-03-24 |
| KR20170104986A (ko) | 2017-09-18 |
| EP3193913B1 (en) | 2022-05-11 |
| TW201625295A (zh) | 2016-07-16 |
| JP6782230B2 (ja) | 2020-11-11 |
| JP2021004268A (ja) | 2021-01-14 |
| JP2017529366A (ja) | 2017-10-05 |
| TW202103730A (zh) | 2021-02-01 |
| AU2015317848A1 (en) | 2017-04-20 |
| US9789170B2 (en) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2915382T3 (es) | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer | |
| ES2805360T3 (es) | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer | |
| ES2828656T3 (es) | Composición que comprende arginina desiminasa pegilada | |
| TWI676683B (zh) | 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶 | |
| HK40075284A (en) | Arginine deiminases with reduced cross reactivity to adi-peg20 antibodies for cancer therapy | |
| HK40041474A (en) | Arginine deiminase with reduced cross-reactivity toward adi-peg 20 antibodies for cancer treatment | |
| HK1214139B (en) | Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment | |
| HK1219232B (en) | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |